Physician profile
Christopher Michael Genco
NPI 1790764827
$2,810.65
in general payments reported to CMS, 2019-2025
13 companies · $501 in 2025
The $501 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2021: $108 · 2022: $674 · 2023: $566 · 2024: $309 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $808.18 | 2019-2025 | Impella |
| Saphena Medical, INC. | $402.64 | 2023 | Venapax |
| Atricure, INC. | $358.81 | 2022-2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Atricure Cryoice Cryosphere Cryoablation System |
| Stryker Corporation | $346.72 | 2022-2023 | Na |
| Abbott Laboratories | $265.92 | 2023-2025 | Epic, Mitraclip |
| Edwards Lifesciences Corporation | $165.54 | 2024 | |
| Janssen Pharmaceuticals, INC | $134.87 | 2019-2022 | |
| Ethicon US, LLC | $121.22 | 2022 | |
| Medical Device Business Services, INC. | $107.69 | 2021 | |
| Clearflow INC. | $46.13 | 2024 | Pleuraflow System With Flowglide |
| Novo Nordisk INC | $21.60 | 2022 | |
| Getinge USA Sales, LLC | $16.43 | 2023 | Cardiohelp |
| Haemonetics Corporation | $14.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Genco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.